Abstract
The efficacy of itraconazole (ITZ) solubilized in hydroxypropyl-β-cyclodextrin (ITZ-IV) was examined in a murine model of invasive pulmonary aspergillosis (IPA). Immunosuppressed mice were infected by the intratracheal inoculation of Aspergillus fumigatus conidia (2 × 106 conidia/mouse). Their body weight rapidly decreased and they died within 6 days after infection. Intravenous administration of various doses of ITZ-IV was started 24 h after infection and was continued once a day for 4 days. ITZ-IV at daily doses of 10, 20, or 40 mg/kg was as effective as the intraperitoneal administration of amphotericin B (AMPH) at a dosage of 1 mg/kg daily in improving survival. ITZ-IV (20 mg/kg per day), as well as AMPH (1 mg/kg per day) significantly lowered the fungal burden in the pulmonary tissues. Histological improvement was seen within 2 days after the beginning of administration of ITZ-IV (20 mg/kg per day). In mice intravenously given a single dose of ITZ-IV (20 mg/kg), the blood level and pulmonary tissue level of ITZ plus its active metabolites, mainly hydroxyitraconazole (OH-ITZ), decreased gradually after the injection, but after 4 h their concentration was still between 1.4 µg/ml (ITZ) and 1.9 µg/ml (OH-ITZ), concentrations that were approximately 10 to 20 times greater than the minimum inhibitory concentration (MIC) of ITZ for challenging the strain of A. fumigatus (0.16 µg/ml). These results support the clinical usefulness of ITZ-IV for the treatment of IPA in immunocompromised patients.
Similar content being viewed by others
References
M Boogaerts J Maertens A van Hoof R de Bock G Fillet M Peetermans et al. (2001) ArticleTitleItraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients J Antimicrob Chemother 48 97–103 Occurrence Handle11418517 Occurrence Handle10.1093/jac/48.1.97 Occurrence Handle1:CAS:528:DC%2BD3MXlsVegtbs%3D
JL Harousseau AW Dekker A Stamatoullas-Bastard A Fassas W Linkesch J Gouveia et al. (2000) ArticleTitleItraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B Antimicrob Agents Chemother 44 1887–93 Occurrence Handle10858349 Occurrence Handle10.1128/AAC.44.7.1887-1893.2000 Occurrence Handle1:CAS:528:DC%2BD3cXksVKksb4%3D
DM MacCallum FC Odds (2002) ArticleTitleEfficacy of parenteral itraconazole against disseminated Candida albicans infection in two mouse strains J Antimicrob Chemother 50 225–9 Occurrence Handle12161403 Occurrence Handle10.1093/jac/dkf072 Occurrence Handle1:CAS:528:DC%2BD38Xms1KmtbY%3D
TF Patterson AW Fothergill MG Rinaldi (1993) ArticleTitleEfficacy of itraconazole solution in a rabbit model of invasive aspergillosis Antimicrob Agents Chemother 37 2307–10 Occurrence Handle8285610 Occurrence Handle1:CAS:528:DyaK2cXksFalsg%3D%3D
H Zhou M Goldman J Wu R Woestenborghs AE Hassell P Lee et al. (1998) ArticleTitleA pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection J Clin Pharmacol 38 593–602 Occurrence Handle9702843 Occurrence Handle1:CAS:528:DyaK1cXltleisrY%3D
L Willems R van der Geest K de Beule (2001) ArticleTitleItraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics J Clin Pharm Ther 26 159–69 Occurrence Handle11422598 Occurrence Handle10.1046/j.1365-2710.2001.00338.x Occurrence Handle1:CAS:528:DC%2BD3MXlt1yksbw%3D
HM Miyazaki S Kohno Y Miyazaki K Mitsutake K Tomono M Kaku et al. (1993) ArticleTitleEfficacy of intravenous itraconazole against experimental pulmonary aspergillosis Antimicrob Agents Chemother 37 2762–5 Occurrence Handle8109952 Occurrence Handle1:CAS:528:DyaK2cXmvV2htQ%3D%3D
AH Groll L Wood M Roden D Mickiene CC Chiou E Townley et al. (2002) ArticleTitleSafety, pharmacokinetics and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis Antimicrob Agents Chemother 46 2554–63 Occurrence Handle12121932 Occurrence Handle10.1128/AAC.46.8.2554-2563.2002 Occurrence Handle1:CAS:528:DC%2BD38XlsFGit7k%3D
PO Gubbins BJ Gurley J Bowman (1998) ArticleTitleRapid, sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum J Pharm Biomed Anal 16 1005–12 Occurrence Handle9547703 Occurrence Handle10.1016/S0731-7085(97)00062-9 Occurrence Handle1:CAS:528:DyaK1cXitFCjt70%3D
InstitutionalAuthorNameNational Committee for Clinical Laboratory Standards (1997) Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard M27-A NCCLS Wayne, PA
SD Stephens-Romero AJ Mednick M Feldmesser (2005) ArticleTitleThe pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy Infect Immun 73 114–25 Occurrence Handle15618146 Occurrence Handle10.1128/IAI.73.1.114-125.2005 Occurrence Handle1:CAS:528:DC%2BD2MXisFOrtw%3D%3D
TM Chiller RA Sobel JC Luque KV Clemons (2003) ArticleTitleEfficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection Antimicrob Agents Chemother 47 813–5 Occurrence Handle12543700 Occurrence Handle10.1128/AAC.47.2.813-815.2003 Occurrence Handle1:CAS:528:DC%2BD3sXhtVWmu7w%3D
RE Lewis RA Prince J Chi DP Kontoyiannis (2002) ArticleTitleItraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis Antimicrob Agents Chemother 46 8208–14
AG Prentice A Glasmacher (2005) ArticleTitleMaking sense of itraconazole pharmacokinetics J Antimicrob Chemother 56 IssueIDSuppl 1 i17–i22 Occurrence Handle16120630 Occurrence Handle10.1093/jac/dki220 Occurrence Handle1:CAS:528:DC%2BD2MXpsVakurw%3D
Q Zhao H Zhou L Pesco-Koplowitz (2001) ArticleTitlePharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection J Clin Pharmacol 41 1319–28 Occurrence Handle11762559 Occurrence Handle10.1177/00912700122012904 Occurrence Handle1:CAS:528:DC%2BD38XmsV0%3D
JH Shin KY Choi YC Kim MG Lee (2004) ArticleTitleDose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect Antimicrob Agents Chemother 48 1756–62 Occurrence Handle15105131 Occurrence Handle10.1128/AAC.48.5.1756-1762.2004 Occurrence Handle1:CAS:528:DC%2BD2cXjslClu7Y%3D
DM MacCallum FC Odds (2002) ArticleTitleInfluence of grapefruit juice on itraconazole plasma levels in mice and guinea pigs J Antimicrob Chemother 50 219–24 Occurrence Handle12161402 Occurrence Handle10.1093/jac/dkf103 Occurrence Handle1:CAS:528:DC%2BD38Xms1Kmurk%3D
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Tansho, S., Abe, S., Ishibashi, H. et al. Efficacy of intravenous itraconazole against invasive pulmonary aspergillosis in neutropenic mice. J Infect Chemother 12, 355–362 (2006). https://doi.org/10.1007/s10156-006-0479-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10156-006-0479-2